Although there are many markers for TCM [14,15,16,17,18], our results indicate that the alteration of frequency of CD45RA−CD27+CD127+ TCM during nivolumab treatment may be a biomarker to predict its therapeutic efficacy in patients with ESCC. This evidence concerns the gene IL7R and esophageal squamous cell carcinoma.